Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
Korean Journal of Clinical Oncology
; (2): 108-115, 2018.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-788037
Biblioteca responsável:
WPRO
ABSTRACT
PURPOSE:
This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival. Secondary endpoints included cardiac safety, tolerability, and overall survival.METHODS:
The study included 60 non-metastatic HER2-positive breast cancer patients. All study patients underwent surgery, received adjuvant chemotherapy, radiotherapy and hormonal therapy if indicated. Thirty patients were randomized in each group. Group I patients received adjuvant trastuzumab for 12 months, while group II patients received adjuvant trastuzumab for 9 months. Patients were assessed by clinical examination and Echocardiography during treatment.RESULTS:
After median follow-up of 12 months, 90% of the patients in group I were disease free and 83.3% of patients in group II were disease free (P=0.402). All studied population in both groups I and II were alive at the end of the 1-year follow-up period after the completion of adjuvant trastuzumab treatment thus overall survival is 100%.CONCLUSION:
Trastuzumab is tolerable and its side effects are reversible. Nine months of adjuvant trastuzumab treatment is more cost effective than the standard 12 months.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Radioterapia
/
Mama
/
Neoplasias da Mama
/
Ecocardiografia
/
Seguimentos
/
Quimioterapia Adjuvante
/
Intervalo Livre de Doença
/
Fator de Crescimento Epidérmico
/
Trastuzumab
Tipo de estudo:
Ensaio clínico controlado
/
Estudo observacional
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Inglês
Revista:
Korean Journal of Clinical Oncology
Ano de publicação:
2018
Tipo de documento:
Artigo